The gut specialists made a welcome return to Geneva to explain how its strain B. bifidum HI-MIMBb75 can be efficacious in these chronic irritable bowel complaints that affect 10-15% of the global population.
Showcasing the strain to potential licensing partners, David Rietbrock, SYNformulas’ Managing Director said, “With strong partners, we would like to further expand our international market presence and are therefore looking forward to stimulating conversations at Vitafoods Europe."
A recent Lancet study detailed the advantages of the non-viable strain over viable bacteria specifically for product stability and standardisation.
In addition, the strain may well be better tolerated as safety concerns have been raised previously for specific patient groups who are susceptible to infection.
The Synformulas-funded study found B bifidum HI-MIMBb75 substantially alleviates irritable bowel syndrome (IBS) and its symptoms in a real-life setting.
These results also indicated that specific beneficial bacterial effects were mediated independently of cell viability.
The Gräfelfing-based firm also highlighted news that the bacterial strain was recently included in the updated S3 guideline irritable bowel syndrome (IBS).
The guidelines are an independent recommendation paper for the diagnosis and treatment of irritable bowel syndrome in clinical practice.
It became the only bacterial strain listed with significant effect on all four leading IBS symptoms, diarrhoea, abdominal pain, flatulence, and constipation.
“We set ourselves the goal to advance the treatment of common diseases such as the irritable bowel syndrome by recommending selected probiotics and further expanding the acceptance of clinically proven therapy options,” said Rietbrock back in Aug 2021.
“The inclusion of the bacterial strain B. bifidum MIMBb75 in the S3 guideline therefore honours us greatly and is a clear sign that Kijimea IBS is a highly relevant therapy option.
“Our patented bacterial strain is the only strain mentioned, which has a significant effect on all four leading symptoms of IBS.”
Synformulas’ product portfolio falls under the Kijimea brand, where B. bifidum HI-MIMBb75 is exclusively contained in Kijimea IBS PRO product.
The product range expands to probiotics, medical devices, dietary supplements and food for special medical purposes that are used to address chronic intestinal complaints and allergies.